Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer
Sponsoring Agencies:
NATL INST OF HLTH NC, NATL SURG ADJUV BREAST & BOWE
